Thinking Through “Breakthrough”: Panel Discussion at the FDA/CMS Summit for Biopharma Executives
This article was originally published in RPM Report
Executive Summary
During The RPM Report’s FDA/CMS Summit for Biopharma Executives December 10, Office of New Drugs Director John Jenkins and Genzyme Senior Policy Advisor Kay Holcombe discussed the dynamics of Breakthrough Therapy during a panel discussion moderated by The RPM Report’s Kate Rawson. Here is a transcript of that discussion.